Last reviewed · How we verify

NCT05178784

EEG Biomarker Study for Participants in the Neurolief "MOOD" Trial

Active, enrolled Last updated 5 December 2024
What this trial tests

trial testing External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) stimulation in Depression in 40 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
16 November 2021
Primary endpoint
3 December 2024
16 November 2025

Quick facts

Lead sponsorButler Hospital
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment40
Start date16 November 2021
Primary completion3 December 2024
Estimated completion16 November 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Butler Hospital

Who can join

Adults 18 to 70, any sex, with Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will collect EEG data at 3 time points from up to 40 adults who are enrolled in a double clinical trial investigating a device that delivers noninvasive, self-administered external Combined Occipital and Trigeminal Neurostimulation (eCOT-NS) treatment for Major Depressive Disorder (Relivion®DP). Baseline (Pre-treatment) Frontal EEG Alpha Oscillations (Power) will be compared post-stimulation power.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Depression

Currently open trials in the same condition.

Other Butler Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05178784.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing